Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Launched by AIDS MALIGNANCY CONSORTIUM · Dec 21, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on collecting blood and tissue samples from individuals to help researchers better understand cancers related to HIV (human immunodeficiency virus) and AIDS (acquired immunodeficiency syndrome). By studying these samples, scientists hope to learn about biological and genetic factors that might link HIV to certain types of cancers, such as anal cancer and lymphomas. This research could lead to improved treatments and better care for people living with HIV.

To participate in this study, you must be at least 18 years old and either be HIV-positive with a diagnosed cancer or HIV-negative with a newly diagnosed or recurrent cancer that is known to be connected to AIDS-related cancers. Participants will be asked to provide blood and tissue samples, and the study is currently recruiting individuals of all genders. Before joining, you will need to give your consent, which means you understand the study and agree to take part. If you qualify, your contributions could play a vital role in advancing our understanding of these important health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must be at least 18 years of age
• * Participant must be HIV- positive and have a diagnosed malignancy. If participants are HIV-negative, they must have a newly diagnosed or recurrent malignancy that has an established scientific connection (e.g., shared etiology) to an AIDS- associated malignancy such as:
• • classic Kaposi sarcoma
• • transplant-associated Kaposi sarcoma,
• • anal cancer,
• • multicentric Castleman's disease,
• • Epstein Barr Virus (EBV) -positive lymphoma
• • plasmablastic lymphoma
• • Hodgkin's lymphoma.
• * For participants that are HIV-positive, HIV infection must be documented by means of any one of the following: :
• • Documentation of HIV diagnosis in the medical record by a licensed health care provider;
• • Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis (PrEP) regimen alone \[e.g., Truvada\], which is exclusionary);
• • HIV ribonucleic acid (RNA) detection by a licensed HIV RNA assay demonstrating \> 1000 RNA copies/mL;
• • Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV Western blot confirmation or HIV rapid multispot antibody differentiation assay.
• • Participants with HIV infection, regardless of participation in an AMC clinical trial, must have a diagnosis of cancer, cancer or a condition that places them at a higher risk of cancer.
• • The investigator determines that the participant (or his/her legally authorized representative \[LAR\]) has the ability to provide informed consent and the participant or LAR provides written informed consent.